FDA Allows IND for DiscGenics’ Clinical Study

FDA accepted DiscGenics' Investigational New Drug Application for a clinical study of its cell therapy product candidate to treat degenerative disc disease (DDD).

In 4Q17, the company will begin U.S. enrollment of 60 patients in a prospective, randomized, double-blinded, vehicle- and placebo-controlled multicenter clinical study to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us